The roles and limitations of bevacizumab in the treatment of ovarian cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
https://link.springer.com/content/pdf/10.1007/s10147-022-02169-x.pdf
Reference36 articles.
1. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2783
2. Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496
3. Nakai H, Matsumura N (2022) Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. Int J Clin Oncol. https://doi.org/10.1007/s10147-022-02163-3 (Online ahead of print)
4. NCCN Clinical Practice Guidelines in Oncology; Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (2021) Version 3. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
5. Bais C, Mueller B, Brady MF et al (2017) Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst 109:djx066
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements;International Journal of Molecular Sciences;2024-02-03
2. Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics;Expert Opinion on Pharmacotherapy;2023-12-12
3. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer;Frontiers in Immunology;2023-10-23
4. Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer;JAMA Network Open;2023-08-02
5. Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer;Pharmaceuticals;2023-06-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3